Anlotinib is a novel multi-kinase inhibitor against both tumor angiogenesis and tumor cell proliferation by blocking vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and stem cell factor receptor c-Kit. This evidence concerns the gene PDGFRB and neoplasm.